Pharmacovigilance of cutaneous adverse drug reactions among patients attending dermatology department at a Tertiary Care Hospital

被引:12
作者
Sharma, Shweta [1 ]
Jayakumar, Dhanya [2 ]
Palappalli, Dhanya S. [3 ]
机构
[1] JJ Hosp, Dept Pharmacol, Grant Govt Med Coll, Mumbai, Maharashtra, India
[2] Govt TD Med Coll Tandanam, Dept Pharmacol, Alappuzha, India
[3] Govt Med Coll, Dept Pharmacol, Kottayam, Kerala, India
关键词
Causality assessment; cutaneous adverse drug reaction; pharmacovigilance;
D O I
10.4103/idoj.IDOJ_419_18
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Context: Cutaneous adverse drug reactions (CADRs) are the most frequent of all manifestations of drug sensitivity that present with varied and diverse morphology and therefore, awareness about them is essential for diagnosis and prevention. Aims: To evaluate the clinical spectrum, morphology, causality, severity and preventability of cutaneous adverse drug reactions in a tertiary care hospital. Setting and Design: Descriptive study for six months in the Dermatology Department of a tertiary care hospital in Kerala. Methods and Materials: All patients of any gender and age who presented with visible skin lesions and were diagnosed or suspected cases of cutaneous adverse drug reactions were included in the study. All the relevant information was recorded using pre-structured proforma and ADR reporting form. Statistical Analysis: Data were analyzed using descriptive statistics. The quantitative variables were expressed as mean +/- standard deviation and qualitative variables as frequencies and percentages. Odds ratio (OR) was calculated to assess the risk factors for severe cutaneous adverse drug reactions using SPSS 16. Results: Total 124 cutaneous adverse drug reactions were reported with mean age 39.22 +/- 20.47 years, male:female ratio being 1:1.4. Most common cutaneous adverse drug reaction was maculopapular rash. Antibiotics accounted for maximum cases, of which beta-lactams were the most common. About 55.6% cutaneous adverse drug reactions occurred within 24 hours of drug administration. Mean hospital stay duration was 4.89 +/- 6.23 days. Most reactions were either mild or moderate. Risk analysis revealed that concomitant use of more than one drug, delayed onset, oral route, more generalized area of involvement and medications prescribed for CNS indications were risk factors for severe cutaneous adverse drug reactions. All reactions were preventable. Majority got fully recovered. No fatality was observed. Conclusion: Identification and reporting of cutaneous adverse drug reactions reduces their future occurrences and encourages rational prescribing. The study emphasizes on having a deeper understanding of risk factors for serious cutaneous adverse drug reactions that may contribute significantly in improving their outcomes.
引用
收藏
页码:547 / 554
页数:8
相关论文
共 50 条
  • [41] A Retrospective Study on Adverse Drug Reactions of Anticancer Drugs in a Tertiary Care Hospital in Northeast India
    Datta, Swagata
    Zosangpuii, Christina
    Ningthoujam, Geetanjali
    Paonam, Shyamasakhi Devi
    Leisangthem, Tarinita devi
    Nameirakpam, Meena devi
    Nameirakpam, Surjit Singh
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2021, 15 (11) : FC1 - FC5
  • [42] An Observational Prospective Study on Prevalence and Monitoring of Adverse Drug Reactions in Tertiary Care Teaching Hospital
    Gangisetty, Sneha
    Nadendla, Sowmya
    Goka, Prem Kumar
    Zahedabano
    Prasanthi, N. Lakshmi
    Rao, Nallani Venkata Rama
    Nadendla, Rama Rao
    BRITISH JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 11 (02):
  • [43] Profile of adverse drug reactions in patients admitted to general surgical wards of a rural tertiary-care hospital in India
    Patel N.
    Desai S.
    Drugs & Therapy Perspectives, 2015, 31 (11) : 402 - 406
  • [44] Evaluation of adverse drug reactions in a pharmacy department: four years of experience of a pharmacovigilance program
    Furelos, Tania Gonzalez
    Legazpi, Iria Rodriguez
    Bueno, Eva Fraga
    Lopez, Monica Granero
    Penin, Isaura Rodriguez
    PHARMACEUTICAL CARE ESPANA, 2025, 27
  • [45] Monitoring Adverse Medication Reactions: Aiding Pharmacovigilance at a Hospital Providing Secondary Care
    Teja, Kommanuru Venkata Ramakrishna
    Reddy, Yiragamreddy Padmanabha
    Devanna, Nayakanti
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2023, 13 (03) : 641 - 645
  • [46] Clinical Pattern and Causality Assessment of Drug-induced Cutaneous Reactions in a Tertiary Care Hospital in India: A Prospective Study
    James, Jerin
    Mohamed, Althab B.
    Hussain, Fayaz S.
    Rani, Jamuna
    Varadarajan, Sathyanarayanan
    CURRENT DRUG SAFETY, 2022, 17 (03) : 193 - 198
  • [47] Adverse drug reactions among patients admitted with infectious diseases at a Brazilian hospital
    Saavedra, Pamela Alejandra
    Milward de Azevedo Meiners, Micheline Marie
    Lopes, Luciane Cruz
    da Silva, Emilia Vitria
    Mendonca da Silva, Dayde Lane
    Noronha, Elza Ferreira
    de Toledo, Maria Ines
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2016, 49 (06) : 763 - 767
  • [48] Prevalence of adverse drug events and adverse drug reactions in hospital among older patients with dementia: A systematic review
    Sakiris, Marissa Anne
    Sawan, Mouna
    Hilmer, Sarah Nicole
    Awadalla, Rebecca
    Gnjidic, Danijela
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (02) : 375 - 385
  • [49] Medication Therapy Management Services and Pharmacovigilance Studies in Tuberculosis Patients: A Patient Care Aspect in the Pulmonology Department in a Tertiary Care Hospital
    Samreen, Sumayya
    Basha, S. A. Azeez
    Aleemuddin, N. M.
    Naaz, Shagufta
    Arshad, Shaik
    Samreen, Fahmeena
    Unnisa, Syeda Zuleqa
    Ali, Syed Amer
    INTERNATIONAL JOURNAL OF MEDICAL RESEARCH & HEALTH SCIENCES, 2019, 8 (05): : 152 - 159
  • [50] Experience of general practitioners from the Northern Department of France in management of cutaneous adverse drug reactions
    Vonarx, M.
    Leurele, V.
    Bene, J.
    Delaporte, E.
    Staumont-Salle, D.
    REVUE FRANCAISE D ALLERGOLOGIE, 2012, 52 (01): : 11 - 19